Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects age 18-80 (inclusive) with confirmed diagnosis of OHT or OAG~* Confirmed diagnosis of bilateral OHT or chronic open-angle glaucoma~* Able to undergo washout of all ocular drugs~* An IOP ≥ 22mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least one eye; but ≤ 35 mmHg at all time points in both eyes on Day -2 and Day -1~* Central corneal thickness 500-600 µm at screening in both eyes~* BCVA 20/100 or better in both eyes~Exclusion Criteria:~* Any history of severe ocular trauma in either eye at any time~* Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of screening visit in the study eye(s)~* Cataracts that prevent observation of the fundus in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm 1 (Type: EXPERIMENTAL): Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
- Experimental Arm 2 (Type: EXPERIMENTAL): Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
- Experimental Arm 3 (Type: EXPERIMENTAL): Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
- Experimental Arm 4 (Type: EXPERIMENTAL): Experimental Eye drop, 2 sequence crossover Cohort \[1 dose; 1-30 µg/mL\]to be determined and placebo
- Placebo Arm (Type: PLACEBO_COMPARATOR): Matched placebo eye drops dosed in same manner as ONO-9054

Based on this trial design, predict the completion outcome and termination type (if applicable).